Proteomics of EBV-infected lytic and refractory cells

ABSTRACT: Most humans are infected with Epstein-Barr virus (EBV), a cancer-causing virus. While EBV generally persists silently in B lymphocytes, periodic lytic (re-)activation of latent virus is central to its life cycle and to most EBV-related diseases. However, a substantial fraction of EBV-infected B cells and tumor cells in a population is refractory to lytic activation. This resistance to lytic activation directly and profoundly impacts viral persistence and effectiveness of oncolytic therapy for EBV+ cancers. To identify the mechanisms that underlie susceptibility to EBV-lytic activation, we used host protein-expression profiling of separated-lytic and -refractory cells.

OTHER RELATED OMICS DATASETS IN: MSV000079993 PRJNA214314

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Cell Culture, Lymphocyte

DISEASE(S): Lymphoma

SUBMITTER: Jizu Zhi  

LAB HEAD: Sumita Bhaduri-McIntosh

PROVIDER: PXD001838 | Pride | 2016-04-27

REPOSITORIES: Pride